The companies will partner on controlled clinical trials in which patients taking a Roche anti-amyloid drug candidate for Alzheimer's disease will be monitored for drug response using GE's positron emission tomography diagnostic imaging agent.
This PET-based technology is able to monitor levels of beta-amyloid, a form of brain plaque believed to cause memory loss in Alzheimer's disease patients. The companies said that this plaque could previously only be confirmed during autopsy.
Roche and GE Healthcare said they will independently analyze patient data and share information to validate the efficacy of the therapeutic product and the PET-based diagnostic tool.
This data will enable Roche and GE to submit "necessary and comprehensive data to regulatory authorities for approvals," the companies said.
Financial terms were not disclosed.